2011年全球制药公司50强排名

作者: 药道人(站内联系TA)收录: 2011-10-20 发布: 2011-10-13

1. Pfizer President and CEO Jeff Kindler retired, succeeded by Ian C. Read. George Lorch elected Non-Executive Chairman of the Board. Sutent approved in EU for treatment of pancreatic neuro-endocrine tumors. Launched Prevnar 13, a vaccine against 13 strains of pneumococcal diseases in infants and young children. Also has 118 products in the R&D pipeline and had 1,300 clinical trials in 2010.

2. Novartis Completed purchase of Alcon from Nestlé for $38.5 billion. Jonathan Symonds promoted to CFO. David Epstein replaced CEO Joe Jimenez as Division Head, Pharmaceuticals. Thirteen major pharmaceutical approvals in the US, Europe, and Japan, with 147 products in development. Tasigna was approved in the US, the EU, Japan, and Switzerland for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a form of blood cancer. Menveo (vaccine against meningococcal disease) launched in the US, EU, and parts of Latin America and Asia. Sandoz launched generic enoxaparin, its most successful launch to date, and acquired Oriel Therapeutics.

3. Sanofi-Aventis Initiated acquisition of Genzyme for $16.6 billion (completed in April) and finished acquisition of OTC company Chattem. Began collaboration programs with Harvard and Columbia Universities and a research alliance with Scripps Genomic Medicine. Jevtana approved in US for second-line treatment of metastatic hormone-refractory prostate cancer.

4. Merck Elected Kenneth Frazier CEO. Bought Inspire for $430 million. Rotateq vaccine awarded top honor at Prix Galien USA 2010. Merck BioVentures entered into an alliance with Parexel for biosimilar development. Signed commercialization agreement with Lundbeck for Sycrest and a letter of mutual intent with China's Sinopharm. Pipeline has more than 20 late-stage candidates. Licensed oral mTOR inhibitor for multiple cancers from Ariad. Oral hepatitis C protease inhibitor Boceprevir granted Priority Review status by FDA.

5. Roche Rituxan approved in US as first-line treatment for chronic lymphocytic leukemia (CLL) and relapsed/refractory CLL. Tarceva approved in US and EU for first-line treatment of non-small-cell lung cancer after chemotherapy. FDA rejected use of Avastin as a treatment for metastatic breast cancer; Roche has requested a hearing to appeal this decision. Daniel O'Day appointed COO of the Pharmaceuticals division. Alan Hippe named CFO. Jean-Jacques Garaud appointed Head of Roche Pharma Research and Early Development.

6. GlaxoSmithKline Benlysta (belimumab, the first new lupus treatment in 60 years) approved by FDA in March. Six products in total approved by US and EU; seven more filed with regulators. Malaria vaccine in Phase III trials in Africa, with 30 other late-stage

assets. Julian Heslop retired as CFO, succeeded by Simon Dingemans. Patents for active ingredients in Seretide/Advair expired.

7. AstraZeneca Crestor substance patent upheld in US court. Approvals include Vimovo (naproxen/esomeprazole magnesium) in US and EU and Brilique (atherothrombotic event prevention) in EU. Kombiglyze XR, the only once-daily dose of DPP4/metformin, developed with Bristol-Myers Squibb, also approved in US. Nine molecules in Phase III trials or submitted for regulatory approval, with another 92 projects in development. Completed deal with Rigel for development of fostamatinib (rheumatoid arthritis).

8. Johnson & Johnson Completed tender offer for Crucell N.V. in February 2011; acquired 98.93 percent of shares. Products under regulatory review include: Rivaroxoban for stroke prevention in patients with atrial fibrillation (US), Telaprevir for hepatitis C (US and EU), Abiraterone acetate for metastatic advanced prostate (US and EU), and rilpivirine for HIV. Eight more candidates planned for regulatory submission from 2011 to 2013.

9. Eli Lilly Completed acquisition of Alnara and Avid Radiopharmaceuticals. Launched statin Livalo in the US with partner Kowa. Has 68 molecules in development. Several monoclonal antibodies for cancer in late-stage development. Phase III candidates include Necitumumab for non-small-cell lung cancer and Ramucirumab for metastatic breast and gastric cancers. Signed commercialization deal with Acrux for newly approved experimental testosterone solution Axiron.

10. Abbott The year was marked by acquisitions, including the pharmaceutical business of Solvay for $6.1 billion plus milestones, and Piramal Healthcare's Healthcare Solutions business, a leader in the Indian branded generics market, for $2.2 billion in cash, plus $1.6 billion in annual payments through 2014. Additional acquisitions included Advanced Medical Optics, STARLIMS Technologies (informatics), and the remaining shares of Facet Biotech.

辉瑞公司总裁兼首席执行官杰夫·金德勒退休，由伊恩·里德继任。乔治·洛奇当选董

事会主席。欧盟批准Sutent治疗胰腺神经内分泌肿瘤疾病。公司推出了肺炎球菌

13价联合疫苗（Prevnar13），一种可以预防13种婴幼儿肺炎链球菌疾病的疫苗株。公司在研项目有118种产品，2010年有1300项临床试验。

诺华以385亿美元完成对爱尔康的收购。乔纳森·西蒙兹晋升为首席财务官。

大卫·爱泼斯坦取代了公司首席执行官乔·希门尼斯，成为公司制药部门主管。诺华

有13种药物在美国、欧洲和日本获得批准，在研产品有147个。Tasigna在美国、

欧盟、日本和瑞士被批准为新诊断的费城染色体阳性慢性髓性白血病（Ph阳性慢

性粒细胞白血病）的治疗。 Menveo（预防脑膜炎双球菌病疫苗）在美国、欧盟、

拉丁美洲和亚洲部分地区上市。旗下的仿制药部门山德士推出依诺肝素钠注射剂。诺华成功收购了Oriel Therapeutics公司。

赛诺菲完成对健赞发起价值166亿美元的收购，并完成了对OTC公司Chattem的收购。公司与哈佛大学、哥伦比亚大学和斯克里普斯基因医学研究联盟

建立合作。Jevtana在美国被批准用于转移性激素难治性前列腺癌的二线治疗。

默沙东选举肯尼思·弗雷泽担任总裁。公司花费4.3亿美元收购眼科药物开发

商Inspire。乐幼康（RotaTeq）疫苗荣获2010年美国Prix Galien（盖伦）大奖赛最

高荣誉。与Parexel结盟，共同开发生物仿制药。公司与Lundbeck签署商业协议开发Sycrest，并与中国的国药控股签订共同意向书。公司研发线有20多种后期候选药。默沙东从Ariad制药公司处获得治疗多种癌症的口服mTOR（雷帕霉素靶蛋白）抑制剂的许可。口服丙型肝炎蛋白酶抑制剂Boceprevir获得美国FDA优先审查资格。

罗氏美罗华在美国被批准用于慢性淋巴细胞白血病（CLL）和复发/难治性白

血病的一线治疗。特罗凯在美国和欧盟被批准用于非小细胞肺癌化疗后一线治疗。美国FDA拒绝了安维汀作为转移性乳腺癌的治疗申请；罗氏已要求听证，对这一

决定提出上诉。公司任命丹尼尔·奥迪为药品部的首席运营官，艾伦·海普为首席财

务官，雅克·伽德为罗氏制药研究及早期开发部主管。

葛兰素史克 Benlysta作为60余年来首个治疗狼疮的药物，在今年3月份获得FDA批准。共有6种产品通过美国和欧盟的批准；7个处于待审核阶段。疟疾疫苗

在非洲处于Ⅲ期试验，30个产品处于晚期试验阶段。西蒙·丁曼斯接替退休的朱利

安赫斯洛普，继任公司首席财务官。舒利迭有效成分的专利到期。

阿斯利康可定的物质专利在美国法院获得支持。美国和欧盟通过对Vimovo （naproxen/esomeprazole magnesium，萘普生/埃索美拉唑镁）的审批，Brilique（动脉粥样硬化事件预防）在欧盟获得批准。与百时美施贵宝公司合作开发的Kombiglyze XR，作为唯一的每日一次剂量的DPP4/metformin，在美国获得批准。

公司有9个新分子实体处于Ⅲ期试验阶段或向监管部门提交批准申请，另有92个

在研项目。公司完成了与Rigel公司合作开发fostamatinib（类风湿关节炎）药物的

事宜。

强生今年2月，强生完成对荷兰生物技术Crucell NV公司的收购要约，收购

对方98.93%的股份。提交监管部门审查的产品包括：用于预防脑卒中患者心房纤

维颤动的Rivaroxoban（美国）、用于丙肝药的Telaprevir（美国和欧盟）、转移性

晚期前列腺治疗药物Abiraterone（美国和欧盟），以及艾滋病治疗药物rilpivirine。公司计划2011~2013年间，向监管部门提出8种以上的候选药物申请。

礼来完成对Alnara和放射性药品生产公司Avid的收购。与日本兴和株式会社在美国启动了对胆固醇药物Livalo的合作。公司目前在研项目有68个分子。几个

用于癌症治疗的单克隆抗体处于后期研发阶段。Ⅲ期试验阶段的候选药物包括非小细胞肺癌治疗药物Necitumumab，以及转移性乳腺癌和胃癌药物Ramucirumab。礼

来与Acrux公司签署商业协议，就新批准的腋下用睾酮缺乏症药物Axiron实验开

展合作。

雅培这一年的特点是收购，包括花费里程碑式的61亿美元收购苏威制药业务；以22亿美元现金、外加到2014年每年共16亿美元的年费，收购印度制药商Piramal Healthcare的旗下品牌仿制药部门。其他收购包括眼力健公司、Starlims技

术公司（信息），以及生物技术公司Facet Biotech的其余股份。